Abel Hall LLC Has $855,000 Stock Position in Amgen Inc. $AMGN

Abel Hall LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 150.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,431 shares of the medical research company’s stock after acquiring an additional 1,460 shares during the period. Abel Hall LLC’s holdings in Amgen were worth $855,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen in the 4th quarter valued at $26,000. Tower View Wealth Management LLC lifted its stake in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Finally, Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 target price on shares of Amgen in a research report on Wednesday, April 8th. Truist Financial lifted their target price on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Mizuho boosted their target price on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Piper Sandler reissued an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Finally, Wells Fargo & Company raised their price target on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $355.50.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $374.15 on Monday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $201.93 billion, a P/E ratio of 26.04, a P/E/G ratio of 3.68 and a beta of 0.41. The stock’s 50-day simple moving average is $342.43 and its two-hundred day simple moving average is $348.09.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm posted $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.39 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.